Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

biologische heilmittel heel gmbh - argentum nitricum d6/atropa bella-donna d10/ceanothus americanus d4/hydrastis canadensis d6/kalium bichromicum d8/kreosotum d12/lachesis d10/mandragora e radice siccata d10/marsdenia cundurango d6/momordica balsamina d6/mucosa coli suis d8/mucosa ductus choledochi suis d8/mucosa ilei suis d8/mucosa jejuni suis d8/mucosa nasalis suis d8/mucosa oculi suis d8/mucosa oesophagi suis d8/mucosa oris suis d8/mucosa pulmonis suis d8/mucosa pylori suis d8/mucosa recti suis d8/mucosa vesicae felleae suis d8/mucosa vesicae urinariae suis d8/oxalis acetosella d6/pankreas suis d10/phosphorus d8/psychotria ipecacuanha d8/pulsatilla pratensis d6/semecarpus anacardium d6/strychnos nux-vomica d13/sulfur d8/ventriculus suis d8/veratrum album d6 - tabletės - 1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg; 1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 m

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivakaftoras - cistinė fibrozė - kiti kvėpavimo sistemos produktai - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ir 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ir 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistinė fibrozė - kiti kvėpavimo sistemos produktai - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

biologische heilmittel heel gmbh (vokietija) - injekcinis tirpalas - mucosa nasalis suis d8 – 0,05 ml; mucosa oris suis d8 – 0,05 ml; mucosa pulmonis suis d8 – 0,05 ml; mucosa oculi suis d8 – 0,05 ml; mucosa vesicae felleae suis d8 – 0,05 ml; mucosa pylori suis d8 – 0,05 ml; mucosa duodeni suis d8 – 0,05 ml; mucosa oesophagi suis d8 – 0,05 ml; mucosa jejuni suis d8 – 0,05 ml; mucosa ilei suis d8 – 0,05 ml; mucosa coli suis d8 – 0,05 ml; mucosa recti suis d8 – 0,05 ml; mucosa ductus choledochi suis d8 – 0,05 ml; mucosa vesicae urinariae sius d8 – 0,05 ml; ventriculus suis d8 – 0,05 ml; pancreas suis d10 – 0,05 ml; argentum nitricum d6 – 0,05 ml; atropa belladona d10 – 0,05 ml; oxalis acetosella d6 – 0,05 ml; semecarpus anacardium d6 – 0,05 ml; phosphorus d8 – 0,05 ml; lachesis mutus d10 – 0,05 ml; ipecacuanha d8 – 0,05 ml; nux vomica d13 – 0,05 ml; veratrum album d4 – 0,05 ml; pulsatilla pratensis d6 – 0,05 ml; kreosotum d10 – 0,05 ml; sulfur d8 – 0,05 ml; bacterium coli-nosode d28 – 0,05 ml; marsdenia cundurango d6 – 0,05 ml; kalium bichromicum d8 – 0,05 ml; hydrastis canadens - fluconazolsvampedrabende.site fluconazol uden recept arkliams, galvijams, kiaulėms, avims, ožkoms, šunims ir katėms esant gleivinės sutrikimams ir katarui, pvz., virškinimo trakto, kvėpavimo ir šlapimo bei lyties takų, akių konjunktyvos, dėl virusinių ligų (panleukopenijos, herpes-, rino-, parvovirusų), lėtinio enterito, otito, konjunktyvito, endometrito. galima naudoti kaip pagalbinę priemonę specifinės terapijos atveju.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cistinė fibrozė - kiti kvėpavimo sistemos produktai - orkambi tabletės yra nurodyta gydyti cistine fibroze (cf) pacientams nuo 6 metų ir vyresni, kurie yra homozigotiniam už f508del mutacija cftr geno. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

pfizer europe ma eeig - bazedoksifenas - osteoporozė, po menopauzės - lytiniai hormonai ir moduliatoriai lytinių organų sistemos, - conbriza skiriamas osteoporozės po menopauzės gydymui moterims, kurioms yra padidėjusi lūžių rizika. Žymiai sumažinti slankstelių lūžių dažnis buvo įrodyta; veiksmingumas dėl šlaunikaulio lūžių nebuvo nustatytas. nustatant pasirinkimas conbriza arba kitais vaistais, įskaitant estrogenai, individualaus po menopauzės moteris, turi būti atsižvelgta į menopauzės simptomus, poveikis gimdos ir krūties audinių, širdies ir kraujagyslių riziką ir naudą.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cistinė fibrozė - kiti kvėpavimo sistemos produktai - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

pfizer europe ma eeig  - pegfilgrastimas - neutropenija - immunostimulants, - neutropenija ir febrili neutropenija sergantiems suaugusiesiems pasireiškimo trukmės mažinimas pacientams, kurių onkologinės ligos (išskyrus lėtinį mieloidinę leukemiją ir mielodisplazinį sindromą).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumabas - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antinavikiniai vaistai - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. daugiau informacijos apie žmogaus epidermio augimo faktoriaus receptorių 2 (her2) būklę rasite 5 skyriuje. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. daugiau informacijos apie her2 statusą rasite 5 skyriuje. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.